Follow-The-Filings

Security · featured owners

MDGL Madrigal Pharmaceuticals Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 3 Owners
  • Max 27.9%
  • $723M
  • 2 reduce 1 exit

MDGL (Madrigal Pharmaceuticals Inc.) is held in 3 featured 13F books as of 2026 Q2. John Paulson - Paulson & Co. is the largest tracked holder by portfolio weight (27.9%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 27.9% (John Paulson - Paulson & Co.) · not free-float ownership

  1. John Paulson reduce 27.9%
  2. Palo Alto Investors 0.13%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
John Paulson - Paulson & Co. 2026 Q2 27.9% Reduce −3.7% 1,340,020 $720M history
Ron Baron - Bamco Inc. (Baron Capital) 2026 Q2 <0.01% Reduce −15.1% 4,500 $2M history
Palo Alto Investors 2026 Q2 0.13% Hold 1,787 $960K history
Farallon Capital Management exited 2026 Q2 last 2026 Q1 0.01% Exit −0.01% 3,319 $2M history

3 current · 1 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 11 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 5.02,7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc
8-K 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 1.01,9.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 14 rows shown

Filed Form Detail Links
4 Period Sep 9, 2026 Filing Doc
4 Period Aug 17, 2026 Filing Doc
4 Period Aug 15, 2026 Filing Doc
4 Period Jul 17, 2026 Filing Doc
4 Period Jun 17, 2026 · 6 forms Filing Doc
4 Period Jun 1, 2026 Filing Doc
4 Period May 22, 2026 Filing Doc
4 Period May 18, 2026 Filing Doc
4 Period Mar 4, 2026 Filing Doc
4 Period Mar 6, 2026 Filing Doc
4 Period Mar 4, 2026 · 4 forms Filing Doc
4 Period Mar 2, 2026 Filing Doc
4 Period Feb 23, 2026 Filing Doc
4 Period Jan 26, 2026 · 4 forms Filing Doc

Updated 10 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $180.13M $958.4M
Gross profit * — $173.9M —
Gross margin * — 96.5% —
Net income -$373.63M -$465.89M -$288.28M
Net margin * — -258.6% -30.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.637B $1.03B $1.25B
Total non-current assets * $3.27M $9.32M $13.82M
Total assets $0.641B $1.04B $1.26B
Total current liabilities $118.55M $169.28M $310.29M
Total non-current liabilities $116.67M $118.59M $346.61M
Total equity $405.33M $754.38M $602.69M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$324.23M -$455.57M -$189.55M
Cash from investing -$502.52M -$274.39M $32.32M
Cash from financing $595.12M $735.06M $255.98M
Net change in cash -$231.63M $5.1M $98.76M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders